Showing results (591-600 of 632) with videos related to
Sort By:
Pageof 64
International Journal of Radiation Oncology, Biology, Physics|June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.International Journal of Radiation Oncology, Biology, Physics|June 19, 2018
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, et al.International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.Journal of Magnetic Resonance Imaging : JMRI|October 9, 2025
Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005Stephanie Alley, Marion Tonneau, Damien Olivié, et al.European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.International Journal of Radiation Oncology, Biology, Physics|September 25, 2016
Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal BleedingJae Y Lee, Stephanie Daignault-Newton, Gerard Heath, et al.The Lancet. Oncology|October 15, 2018
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trialMack Roach, Jennifer Moughan, Colleen A F Lawton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.Plos One|April 14, 2021
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, et al.European Urology Focus|February 2, 2024
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202Kimberley S Mak, Molly Scannell Bryan, James J Dignam, et al.Pageof 64